logo
  

Elevation Oncology, Inc. Q4 Loss decreases, beats estimates

Elevation Oncology, Inc. (ELEV) reported Loss for fourth quarter that decreased from the same period last year and beat the Street estimates.

The company's earnings totaled -$7.899 million, or -$0.19 per share. This compares with -$19.042 million, or -$0.82 per share, in last year's fourth quarter.

Analysts on average had expected the company to earn -$0.24 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

Elevation Oncology, Inc. earnings at a glance (GAAP) :

-Earnings (Q4): -$7.899 Mln. vs. -$19.042 Mln. last year.
-EPS (Q4): -$0.19 vs. -$0.82 last year.

For comments and feedback contact: editorial@rttnews.com

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
RELATED NEWS
Follow RTT